378 related articles for article (PubMed ID: 38057451)
1. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations.
Butterfield LH; Najjar YG
Nat Rev Immunol; 2024 Jun; 24(6):399-416. PubMed ID: 38057451
[TBL] [Abstract][Full Text] [Related]
2. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
3. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
4. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
[TBL] [Abstract][Full Text] [Related]
5. Combination strategies to maximize the benefits of cancer immunotherapy.
Zhu S; Zhang T; Zheng L; Liu H; Song W; Liu D; Li Z; Pan CX
J Hematol Oncol; 2021 Sep; 14(1):156. PubMed ID: 34579759
[TBL] [Abstract][Full Text] [Related]
6. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
Zhu MMT; Shenasa E; Nielsen TO
Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
[TBL] [Abstract][Full Text] [Related]
7. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
[TBL] [Abstract][Full Text] [Related]
8. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapies and Combination Strategies for Immuno-Oncology.
Barbari C; Fontaine T; Parajuli P; Lamichhane N; Jakubski S; Lamichhane P; Deshmukh RR
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679922
[TBL] [Abstract][Full Text] [Related]
10. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy.
Pan C; Liu H; Robins E; Song W; Liu D; Li Z; Zheng L
J Hematol Oncol; 2020 Apr; 13(1):29. PubMed ID: 32245497
[TBL] [Abstract][Full Text] [Related]
11. Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.
Appleton E; Hassan J; Chan Wah Hak C; Sivamanoharan N; Wilkins A; Samson A; Ono M; Harrington KJ; Melcher A; Wennerberg E
Front Immunol; 2021; 12():754436. PubMed ID: 34733287
[TBL] [Abstract][Full Text] [Related]
12. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.
Malogolovkin A; Gasanov N; Egorov A; Weener M; Ivanov R; Karabelsky A
Viruses; 2021 Jun; 13(7):. PubMed ID: 34209981
[TBL] [Abstract][Full Text] [Related]
14. Microbial biomarkers for immune checkpoint blockade therapy against cancer.
Adachi K; Tamada K
J Gastroenterol; 2018 Sep; 53(9):999-1005. PubMed ID: 30003334
[TBL] [Abstract][Full Text] [Related]
15. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
16. Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.
Gatti-Mays ME; Redman JM; Collins JM; Bilusic M
Hum Vaccin Immunother; 2017 Nov; 13(11):2561-2574. PubMed ID: 28857666
[TBL] [Abstract][Full Text] [Related]
17. [A decade of checkpoint inhibitors: current standard of care and future trends].
Reischer A; Kruger S; von Bergwelt-Baildon M
Dtsch Med Wochenschr; 2021 Sep; 146(17):1108-1118. PubMed ID: 34448187
[TBL] [Abstract][Full Text] [Related]
18. SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.
Hu-Lieskovan S; Bhaumik S; Dhodapkar K; Grivel JJB; Gupta S; Hanks BA; Janetzki S; Kleen TO; Koguchi Y; Lund AW; Maccalli C; Mahnke YD; Novosiadly RD; Selvan SR; Sims T; Zhao Y; Maecker HT
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33268350
[TBL] [Abstract][Full Text] [Related]
19. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
20. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
Zappasodi R; Merghoub T; Wolchok JD
Cancer Cell; 2018 Apr; 33(4):581-598. PubMed ID: 29634946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]